T7744

Piperaquine tetraphosphate tetrahydrate is a potent anti-parasites agent.

Apitegromab (SRK-015) is a new myostatin inhibitor, an antibody targeting myostatin precursor, which can be used to study neuromuscular diseases including spinal muscular atrophy.

Codrituzumab (GC3) is a humanized antibody against the glypican-3 hepatocellular carcinoma protein that can be used in combination with sorafenib to study incurable advanced hepatocellular carcinoma (HCC).

KRN330 is a fully human anti-A33 monoclonal antibody that can be used to study advanced rectal cancer.

Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is a mouse γ-type anti-recombinant antibody that specifically induces an antibody response against Neu-glycolyl GM3 ganglioside (NeuGcGM3), overexpressed in various solid tumors. Racotumomab reacts with gangliosides containing Neu-Glycolyl (NeuGc), thioglycosides, and other tumor-expressed antigens, demonstrating anti-cancer activity, and is used in lung cancer research.

Ecromeximab (KW2871) is a mouse chimeric monoclonal antibody targeting ganglioside GD3 and can be used to study malignant melanoma.

Dinutuximab is a recombinant chimeric monoclonal antibody targeting GD2, with potential anti-cancer activity, used in high-risk neuroblastoma research.

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers.

Tabituximab (ONC-005) is a humanized monoclonal antibody targeting frizzled class receptor 10 (FZD10) with antitumor activity for the study of immune system diseases.